ALLMedicine™ Inflammatory Breast Cancer Center

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To determine the pathologic complete response (pCR) rate in patients with primary triple-receptor negative (estrogen receptor [ER]-negative, progesterone receptor [PgR]-negative, and human epidermal growth factor receptor 2 ...

Jun 24th, 2022 - Inflammatory breast cancer (IBC) is an aggressive phenotype with a high recurrence and low survival rate. Approximately 90% of local breast cancer recurrences occur adjacent to the same quadrant as the initial cancer, implying that tumor recurrenc...

Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To compare the invasive disease-free survival (IDFS) of patients with inflammatory breast cancer receiving concurrent administration of olaparib with standard doses of radiotherapy to the chest wall and regional lymph nodes c...

Jun 21st, 2022 - PRIMARY OBJECTIVE: I. To determine the pathological complete response (pCR rate) of the proposed combination in patients with newly diagnosed triple-negative inflammatory breast cancer (TN-IBC). SECONDARY OBJECTIVES I. To evaluate the surgical com...

Jun 18th, 2022 - The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, i...

Jul 7th, 2010 - Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published t...

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To determine the pathologic complete response (pCR) rate in patients with primary triple-receptor negative (estrogen receptor [ER]-negative, progesterone receptor [PgR]-negative, and human epidermal growth factor receptor 2 ...

Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To compare the invasive disease-free survival (IDFS) of patients with inflammatory breast cancer receiving concurrent administration of olaparib with standard doses of radiotherapy to the chest wall and regional lymph nodes c...

Jun 21st, 2022 - PRIMARY OBJECTIVE: I. To determine the pathological complete response (pCR rate) of the proposed combination in patients with newly diagnosed triple-negative inflammatory breast cancer (TN-IBC). SECONDARY OBJECTIVES I. To evaluate the surgical com...

Apr 29th, 2022 - PRIMARY OBJECTIVES: I. To prospectively collect tissue (including primary inflammatory breast cancer [IBC], ipsilateral nodal metastasis and/or distant metastasis [if applicable] obtained prior to primary systemic therapy and mastectomy/axillary d...

Apr 13th, 2022 - PRIMARY OBJECTIVES: I. To determine maximum tolerated dose (MTD) of icosapent ethyl (EPA) and dasatinib in patients with metastatic triple negative inflammatory breast cancer (mTN-IBC). (Phase 1b) II. To determine the overall response rate (ORR) o...

Mar 15th, 2022 - Mikkael Sekeres, MD, MS The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 13-0 with one abstention in support of pertuzumab (Perjeta) in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoad...

Feb 17th, 2022 - NEW YORK (Reuters Health) - Sentinel-lymph-node biopsies are frequently and increasingly being used in patients with inflammatory breast cancer, contrary to guidelines which recommend axillary-lymph-node dissection for these women, a new study sho...

Oct 6th, 2021 - Debu Tripathy, MD Although targeting cyclin-dependent kinase (CDK) 4/6 has proved to be a successful strategy in the management of postmenopausal women with hormone receptor (HR)— positive, HER2-negative advanced breast cancer, there is an unmet ...

Oct 6th, 2021 - Eileen Connolly, MD, PhD, an assistant professor of radiation oncology at Columbia University Medical Center, discusses the possible benefit of postmastectomy radiation for patients with breast cancer. Postmastectomy radiation has traditionally b...

Oct 6th, 2021 - Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented durin...